In a report released today, Ritu Baral from TD Cowen maintained a Buy rating on Madrigal Pharmaceuticals (MDGL – Research Report), with a price target of $390.00.
Ritu Baral has given her Buy rating due to a combination of factors including Madrigal Pharmaceuticals’ strong financial performance and strategic market positioning. The company reported impressive first-quarter 2025 revenues of $137 million for its product Rezdiffra, significantly surpassing both consensus and buyside expectations. This robust revenue growth indicates a successful product launch and a promising trajectory for continued expansion.
Additionally, Madrigal Pharmaceuticals has a solid cash position of $848 million, which provides a sufficient financial runway for ongoing trials and future product launches in the US and EU. The company’s strategic targeting of top-tier physicians and the broad insurance coverage for Rezdiffra further bolster its market penetration efforts. These factors collectively contribute to a positive outlook for Madrigal Pharmaceuticals, justifying the Buy rating.
In another report released today, JMP Securities also reiterated a Buy rating on the stock with a $470.00 price target.
Based on the recent corporate insider activity of 53 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of MDGL in relation to earlier this year.